EX-21.1 8 exhibit211-subsidiaries.htm EXHIBIT 21.1 Exhibit


Exhibit 21.1

Subsidiaries

Name of Subsidiary
 
Jurisdiction of Incorporation or Organization
 
Percentage of Ownership by the Registrant
BeiGene 101
 
Cayman Islands
 
100
%
BeiGene AUS Pty Ltd.
 
Australia
 
100
%
BeiGene (Beijing) Co., Ltd.
 
People’s Republic of China
 
100
%
BeiGene Biologics Co., Ltd.
 
People’s Republic of China
 
95
%
BeiGene (Canada) ULC
 
Canada
 
100
%
BeiGene ESP, S.L.
 
Spain
 
100
%
BeiGene France Sarl
 
France
 
100
%
BeiGene Germany GmbH
 
Germany
 
100
%
BeiGene Guangzhou Biologics Manufacturing Co., Ltd.
 
People’s Republic of China
 
95
%
BeiGene (Guangzhou) Co., Ltd.
 
People’s Republic of China
 
100
%
BeiGene (Hong Kong) Co., Limited
 
Hong Kong
 
100
%
Beijing Innerway Bio-tech Co., Ltd.
 
People’s Republic of China
 
100
%
BeiGene (Italy) Sarl
 
Italy
 
100
%
BeiGene Ireland Limited
 
Republic of Ireland
 
100
%
BeiGene Korea Y.H.
 
Korea
 
100
%
BeiGene Pharmaceuticals (Guangzhou) Co., Ltd.
 
People’s Republic of China
 
100
%
BeiGene Pharmaceutical (Shanghai) Co., Ltd.
 
People’s Republic of China
 
100
%
BeiGene (Shanghai) Co., Ltd.
 
People’s Republic of China
 
95
%
BeiGene (Shanghai) Research & Development Co., Ltd.
 
People’s Republic of China
 
100
%
BeiGene Singapore Pte., Ltd.
 
Singapore
 
100
%
BeiGene (Suzhou) Co., Ltd.
 
People’s Republic of China
 
100
%
BeiGene Switzerland GmbH
 
Switzerland
 
100
%
BeiGene (Taiwan) Limited
 
Republic of China
 
100
%
BeiGene UK, Ltd.
 
United Kingdom
 
100
%
BeiGene United Kingdom, Ltd.
 
United Kingdom
 
100
%
BeiGene USA, Inc.
 
United States
 
100
%
Mapkure, LLC
 
United States
 
71
%